Page 1

30 September 2026 Avingtrans plc ( " Avingtrans " , the " Company " , or the " Group " ) Preliminary results for the year ended 31 May 2026 Avingtrans PLC ( AIM : AVG ) , which designs , manufactures and supplies critical components , modules , systems and associated services to the energy , medical and industrial sectors , is pleased to announce its preliminary results for the year ended 31 May 2026 . Financial Highlights Revenue from operations increased by 4.4 % to a record £ 163.3m ( 2025 : £ 156.4m ) Gross Margin increased to 32.8 % ( 2025 : 31.7 % ) Adjusted¹ EBITDA from continuing operations was slightly ahead of the previously upgraded market expectations at £ 20.7m ( 2025 : £ 16.7m ) . AES recorded a 11.7 % uplift in adjusted EBITDA across the division to £ 24.0m , offset by a smaller than forecast investment in the MII division Adjusted¹ PBT from operations was £ 12.5m ( 2025 : £ 8.6m ) , reflecting strong underlying growth in AES results alongside lower medical costs Adjusted¹ diluted earnings per share from continuing operations was 31.3p ( 2025 : 23.7p ) Net Debt ( excluding IFRS16 ) at 31 May 2026 of £ 11.8m ( 31 May 2025 : £ 12.3m ) , improved position ahead of market expectations Final dividend of 3.1p per share proposed , resulting in a total dividend of 5.1p per share ( 2025 : 4.9p ) Adjusted to add back amortisation of intangibles from business combinations , acquisition costs and exceptional items Operational Highlights Energy ( AES ) Austen Adams appointed as Chief Operating Officer ( COO ) of the Avingtrans Group in November 2025 Revenue increased by 4.1 % to a record £ 157.6m ( 2025 : £ 151.5m ) Adjusted EBITDA up 11.7 % to £ 24.0m ( 2025 : £ 21.5m ) Strong performance by Hayward Tyler , driven by rapid global growth in AI and data centre infrastructure , electrification of transport and links to new nuclear power requirements HT Inc won $ 16.0m of new nuclear contracts with KHNP of South Korea Positive progress made in HT Inc's $ 10.0m contract with TerraPower , for novel nuclear pumps Ormandy continued strong results , benefitting from growth in energy demanding AI and data centres Metalcraft continues to ramp - up 3M3 box production phase for Sellafield Booth won additional contracts with HS2 and TfL worth £ 8.5m - production ramp - up progressing US tariffs in the period impacted S & P recovery , resulting in some restructuring in Q1 FY27 Medical ( MII ) Stuart Gall appointed as Divisional CEO of MII in January 2026 Revenue increased to £ 5.7m ( 2025 : £ 4.9m ) , pending build - up of new MRI and X - ray products Adjusted¹ LBITDA decreased to £ 2.2m ( 2025 : £ 3.6m ) as new MRI and X - ray products progress to market Adaptix gained 510 ( k ) ( US FDA ) and CE mark approval allowing orthopaedic system sales to commence Adaptix appointed multiple distributors in the UK , USA , and Europe across three addressable market sectors Adaptix won its first material NDT contract , order funnel at record high in particular for aerospace inspection Magnetica continues to progress its delayed 510 ( k ) approval process SciMag seeing increased orders for magnet and cryogenic systems used in quantum computing Current Trading & Outlook In the quarter since 31 May 2026 , the Group has performed in line with management expectations , with the strong momentum of FY26 continuing into FY27 , bolstered by a series of contract wins in AES and MII Post period end , oversubscribed £ 20 million net placing to provide Avingtrans with the resources to accelerate its expansion plans for Hayward Tyler , enabling it to invest to satisfy known customer demand The Board remains confident about the current strategic direction and potential future opportunities across both the AES & MII divisions , whilst continually monitoring market conditions We will continue to refine our business by pinpointing specific additional acquisitions as the opportunities arise , to generate superior shareholder value , whilst maintaining a conservative approach